Moderate-To-Severe Crohn's Disease (Pediatric, Ages 2+)
TAKTakedaCatalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for Entyvio/Vedolizumab (Vedolizumab) (Integrin Inhibitor) in Moderate-To-Severe Crohn's Disease (Pediatric, Ages 2+). The expected timing is based on the latest available company guidance and may change.
07/30/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.